A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine (Q33401523)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine |
scientific article |
Statements
1 reference
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine (English)
1 reference
Shanu Modi
1 reference
Kathy D Miller
1 reference
Hope S Rugo
1 reference
Denise Yardley
1 reference
Eric P Winer
1 reference
Ian E Krop
1 reference
Patricia LoRusso
1 reference
Gladys Rodriguez
1 reference
Ellie Guardino
1 reference
Michael Lu
1 reference
Maoxia Zheng
1 reference
Sandhya Girish
1 reference
Lukas Amler
1 reference
1 reference
Identifiers
1 reference